| Clonal hematopoiesis |
pubmed |
("canakinumab"[Title/Abstract] OR anakinra[Title/Abstract]) AND ("clonal hematopoiesis"[Title/Abstract] OR CHIP[Title/Abstract] OR "clonal haematopoiesis"[Title/Abstract]) AND (microvascular[Title/Abstract] OR erythromelalgia[Title/Abstract] OR CANTOS[Title/Abstract] OR cardiovascular[Title/Abstract] OR "clonal expansion"[Title/Abstract] OR "clonal fitness"[Title/Abstract] OR endothelial[Title/Abstract]) |
Targets canakinumab/anakinra specifically with CHIP plus microvascular, clonal-fitness, or CANTOS/cardiovascular endpoints, catching confirming or disproving evidence in MPN and adjacent CHIP populations not covered by the existing fatigue/IL-1×MPN/CHIP or CHIP×JAK2×microvascular queries. |
active |
| Thrombosis risk |
pubmed |
("bomedemstat"[Title/Abstract] OR "IMG-7289"[Title/Abstract] OR "MK-3543"[Title/Abstract] OR "LSD1 inhibitor"[Title/Abstract] OR "LSD1 inhibition"[Title/Abstract]) AND ("thrombosis"[Title/Abstract] OR "thrombotic"[Title/Abstract] OR "thromboembolic"[Title/Abstract] OR "platelet mass"[Title/Abstract] OR "platelet count"[Title/Abstract] OR "arterial thrombosis"[Title/Abstract] OR "venous thrombosis"[Title/Abstract]) |
Links bomedemstat/LSD1 to thrombosis and platelet-mass endpoints (confirming or disproving) without requiring MPN disease terms already covered by existing bomedemstat queries. |
active |
| Bone marrow fibrosis |
pubmed |
"pitavastatin"[Title/Abstract] AND (fibrosis[Title/Abstract] OR fibrocyte[Title/Abstract] OR fibrocytes[Title/Abstract] OR "TGF-beta"[Title/Abstract] OR "TGF-β"[Title/Abstract] OR "TGF-β1"[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "marrow fibrosis"[Title/Abstract] OR "bone marrow"[Title/Abstract]) |
Targets pitavastatin specifically with fibrosis/fibrocyte/TGF-β endpoints across MPN and adjacent contexts, catching confirming or disconfirming evidence not covered by any existing statin-free or broad fibrosis queries. |
active |
| Inflammatory cytokine signaling |
pubmed |
pacritinib[Title/Abstract] AND (fatigue[Title/Abstract] OR "symptom burden"[Title/Abstract] OR MyD88[Title/Abstract] OR "IL-1"[Title/Abstract] OR "IL-6"[Title/Abstract] OR IRAK1[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR myeloproliferative[Title/Abstract] OR MPN[Title/Abstract] OR cytokine[Title/Abstract]) |
Targets pacritinib’s JAK2/IRAK1–MyD88–IL-1/IL-6 axis and fatigue/symptom outcomes beyond the existing pacritinib OR myelofibrosis/thrombocytopenia/IRAK1 query, catching confirming or disconfirming evidence. |
active |
| ASTX727 (oral cedazuridine + decitabine) |
pubmed |
("ASTX727"[Title/Abstract] OR cedazuridine[Title/Abstract] OR Inqovi[Title/Abstract] OR "decitabine-cedazuridine"[Title/Abstract] OR "decitabine cedazuridine"[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR MPN[Title/Abstract] OR MDS[Title/Abstract] OR CMML[Title/Abstract] OR "myelodysplastic"[Title/Abstract] OR AML[Title/Abstract] OR "chronic myelomonocytic"[Title/Abstract]) |
Targets the oral cedazuridine/decitabine fixed-dose product (ASTX727/Inqovi) by name, which existing decitabine/azacitidine and hypomethylating-agent queries do not specifically cover. |
active |
| Azacitidine + Venetoclax + Gilteritinib combination |
pubmed |
"gilteritinib"[Title/Abstract] AND "venetoclax"[Title/Abstract] AND ("azacitidine"[Title/Abstract] OR azacytidine[Title/Abstract] OR "5-AZA"[Title/Abstract]) AND (FLT3[Title/Abstract] OR AML[Title/Abstract] OR MDS[Title/Abstract] OR CMML[Title/Abstract] OR "MDS/MPN"[Title/Abstract] OR myeloproliferative[Title/Abstract]) |
Targets the specific Aza+Ven+Gilt triplet and FLT3/MDS-MPN context; existing queries cover azacitidine broadly or other agents but none combine gilteritinib with venetoclax and a hypomethylating agent. |
active |
| Fedratinib |
pubmed |
("Inrebic"[Title/Abstract] OR "SAR302503"[Title/Abstract] OR "TG101348"[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR MPN[Title/Abstract] OR "JAK2"[Title/Abstract]) |
Existing fedratinib query only matches the generic name; this catches brand and legacy code names (Inrebic/SAR302503/TG101348) used in older or label-focused MPN literature that would otherwise be missed. |
active |
| XPO1 nuclear export |
pubmed |
("XPO1"[Title/Abstract] OR "exportin-1"[Title/Abstract] OR "exportin 1"[Title/Abstract] OR selinexor[Title/Abstract]) AND (myelofibrosis[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract]) |
Catches XPO1/exportin-1 mechanism and selinexor monotherapy or non-ruxolitinib combination papers in MPN that the existing selinexor+ruxolitinib-only query misses. |
active |
| Mutant-selective JAK2V617F inhibition via JH2 pseudokinase domain |
pubmed |
"PRT12396"[Title/Abstract] OR (("JH2"[Title/Abstract] OR "pseudokinase domain"[Title/Abstract]) AND "JAK2"[Title/Abstract] AND (allosteric[Title/Abstract] OR "mutant-selective"[Title/Abstract] OR inhibitor[Title/Abstract]) AND (myeloproliferative[Title/Abstract] OR myelofibrosis[Title/Abstract] OR "polycythemia vera"[Title/Abstract] OR "V617F"[Title/Abstract])) |
Retrieves JH2/pseudokinase-directed and mutant-selective JAK2V617F inhibitor papers (including PRT12396) that broad JAK2 V617F, JAK-STAT, pan-JAK, and type II JH1 queries do not specifically cover. |
active |
| MPL mutations |
pubmed |
("thrombopoietin receptor"[Title/Abstract] OR "TPO-R"[Title/Abstract] OR "c-MPL"[Title/Abstract]) AND (W515[Title/Abstract] OR S505N[Title/Abstract] OR "exon 10"[Title/Abstract] OR "activating mutation"[Title/Abstract]) AND ("essential thrombocythemia" OR myelofibrosis OR myeloproliferative) |
Catches TPO-R/c-MPL nomenclature and non-W515L/K variants (S505N, exon 10, other W515) without requiring the gene symbol MPL, which the existing MPL-focused dynamic query always mandates. |
active |